Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Infectious disease

Lilly will test baricitinib against COVID-19

by Michael McCoy
April 18, 2020 | A version of this story appeared in Volume 98, Issue 15
Advertisement

Most Popular in Biological Chemistry

 

The structure of baricitinib.

Eli Lilly and Company and the US National Institute of Allergy and Infectious Diseases will study baricitinib, a Lilly rheumatoid arthritis drug, as a potential treatment for people with COVID-19. It’s thought that baricitinib’s anti-inflammatory effect could help reduce the cytokine storm that COVID-19 can trigger in patients. Ruxolitinib, a cancer treatment from Novartis and Incyte, is also being tested for its potential to dampen the cytokine storm.

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

CORRECTION

This story was updated on April 20, 2020, to correctly state the partners that market ruxolitinib. They are Novartis and Incyte, not Novartis and Regeneron.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society

You might also like...

AstraZeneca licenses small-molecule heart drug from China’s CSPC
FDA approves Pfizer ulcerative colitis drug Velsipity
Serving the chemical, life science, and laboratory worlds
Lilly arthritis drug approved for alopecia

Article:

This article has been sent to the following recipient:

3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE